echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Commercialization test transcript: 34 18A pharmaceutical companies have revenue of 25.3 billion yuan and 60% have experienced market value shrinkage

    Commercialization test transcript: 34 18A pharmaceutical companies have revenue of 25.3 billion yuan and 60% have experienced market value shrinkage

    • Last Update: 2022-06-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2021, the 18A biotechnology company in Hong Kong stock market will gradually realize the innovation results
    .

    In the past month, the 2021 results of Hong Kong-listed pharmaceutical companies have almost been announced one after another.
    Among them, Biotechs in the 18A sector almost represent the innovation strength of domestic biotechnology companies

    .
    According to the statistics of E-pharmaceutical managers, as of the close of trading on the afternoon of April 15, a total of 34 18A biotechnology companies have announced their 2021 results (35 in total, and CStone has delayed disclosure), and the total revenue has reached 25.
    348 billion yuan, which is higher than the previous 9.
    789 billion yuan in the same period last year, a 159% increase

    .

    However, as the trend of "squeezing the bubble" in 2021 becomes more prominent, the total market value of 34 18A biotechnology companies in 2021 will shrink by HK$19.
    8 billion compared with 26 in 2020

    .
    Specifically, among the listed companies in 2020 and before, only 8 companies have achieved market value growth, and the other 17 companies have experienced "shrinkage" to varying degrees, with a "shrinkage" ratio of 65%

    .

    In terms of R&D expenses, 18A biotechnology companies are also continuing to accelerate.
    BeiGene leads the way with R&D investment of 9.
    308 billion yuan.
    The average growth rate of R&D expenses of 34 companies is 41%, and the highest growth rate is 701%

    .

    At the same time, with the accelerated upgrade of innovation level, the cooperation of BD projects has become more popular.
    The two license-out cooperation between BeiGene and Novartis in 2021 will total more than 5 billion US dollars; up to $2.
    6 billion

    .
    On the other hand, the number and mode of cooperation between Biotech, Biotech and Biopharma, and BigPharma have all changed.
    .
    .

    01 Commercialization: The innovation achievements of leading enterprises are emerging

    01 Commercialization: The innovation achievements of leading enterprises are emerging

    In 2021, 26 of the 34 18A biotech companies achieved revenue, with a total revenue of 25.
    945 billion yuan, and the revenue of the top Biotech company contributed most of it

    .

    The highest annual revenue is BeiGene, with annual revenue of 1.
    176 billion US dollars (about 7.
    492 billion yuan), a year-on-year increase of 280.
    8%, and a loss of about 1.
    3 billion yuan less than last year, a year-on-year decrease of 13%

    .
    The revenue of CanSino, Cinda, and Junshi is all around 4 billion yuan, of which Junshi’s loss decreased by 56.
    8% year-on-year, while CanSino turned losses into profit, with total revenue increasing by 23086.
    49%

    .

    The realization of innovation achievements has become the main driving force for their revenue growth
    .

    Half of BeiGene's revenue comes from commercial product contributions
    .
    By the end of 2021, BeiGene's commercial products have increased to 16 models, with a total revenue of 4 billion yuan, a year-on-year increase of 105%

    .
    Among them, the highest revenue is its PD-1 product tislelizumab, with sales totaling 1.
    6 billion yuan, a year-on-year increase of 56%

    .
    As of April 15, the number of domestically approved indications for tislelizumab has reached 8, of which 5 are included in the national medical insurance

    .

    Another product, BTK inhibitor zanubrutinib, shows that BeiGene’s internationalization process is moving towards independent commercialization.
    In 2021, zanubrutinib’s global sales will be about 1.
    4 billion yuan, a year-on-year increase of 423%.
    Revenue reached about 700 million yuan, a year-on-year increase of 535%

    .
    Zanubrutinib is currently approved in 45 countries and regions around the world

    .

    The turnaround of CanSino in 2021 is mainly due to the approval and commercialization of its new crown vaccine at home and abroad
    .
    Its annual report shows that CanSino’s new crown vaccine has been approved for marketing in more than 9 overseas countries and regions since it was approved for marketing in China with conditions in February 2021

    .
    In addition, CanSino's commercial products include two meningococcal vaccines and one Ebola vaccine

    .
    Among them, the meningococcal vaccine MCV4 is a newly approved product in 2021 and is the first quadrivalent meningitis conjugate vaccine approved for marketing in China

    .

    The most important boost to Junshi Bio's performance in 2021 is the neutralizing antibody ectelizumab, which is cooperating with Eli Lilly.
    Although Junshi Bio did not disclose the specific revenue of this product in the annual report, the sales in the main business sub-regions Among them, Junshi's overseas revenue was as high as 3.
    341 billion yuan, a year-on-year increase of 562.
    66%

    .
    The previous annual report of Eli Lilly disclosed that the annual sales of new crown neutralizing antibodies were 2.
    239 billion US dollars

    .

    However, Junshi's PD-1 sales are not optimistic.
    Its annual sales of toripalimab are only 412 million yuan, less than half of last year's 1.
    003 billion yuan, while sales volume has increased by 17.
    53% over the same period last year.
    %, it seems that the "price-for-volume" for entering medical insurance has not been achieved

    .
    Junshi's annual report explained that on the one hand, it came from the drop in medical insurance by more than 60%, and on the other hand, after the 2021 version of the National Medical Insurance Catalogue and further price reductions, the company compensated the price difference for all the dealers' inventory, and the current products Revenue recognition has a certain impact

    .
    In addition, in 2021, the adjustment of Junshi's commercialization team will be relatively turbulent, the team's execution ability will decline, and market activities cannot be implemented stably

    .
    "As an innovative drug company in a period of rapid development, the setbacks encountered on the road to commercialization are temporary,

    " Junshi Bio concluded in its annual report
    .

    Innovent's product revenue will reach 4 billion yuan in 2021, a year-on-year increase of 69%, and its commercial product portfolio has reached 6 models, of which the sales growth of the PD-1 product sintilimab is the main driving force for performance growth.

    .
    According to the quarterly sales of sintilimab previously disclosed by Cinda, the total annual sales of the product exceeded 3 billion yuan, and the figure for 2020 is still 2.
    29 billion yuan

    .

    The high sales growth of Cinda is not unrelated to the expansion of its commercialization capabilities.
    The annual report shows that the sales investment reached 2.
    541 billion yuan last year, and the scope of commercialization channels has been expanded to about 5,100 hospitals and 1,100 DTP pharmacies in more than 320 cities.
    The number of personnel has also increased from 1,284 in 2020 to 2,768 in 2021

    .
    It can be seen from the product portfolio and commercialization capabilities that Innovent is taking a further step in its evolution to Biopharma

    .

    The head biotechnology companies are transforming into Biopahrma, and the "small and beautiful" companies in 18A are also gradually commercializing their products
    .

    As a leading company in the domestic ADC field, Rongchang Bio will achieve operating income of 1.
    426 billion yuan in 2021, of which technology licensing revenue from HER2 ADC drugs will be 1.
    291 billion yuan, and product sales revenue will be 131 million yuan

    .

    Hua Medicine, which focuses on the field of diabetes, also took a key step in 2021, submitting a new drug application for Dorzagliatin for the treatment of type 2 diabetes to the NMPA for acceptance
    .

    Ascentage Pharma, which focuses on apoptosis, has entered the commercialization stage with the approval of its first product, Orebatinib, in November 2021
    .
    On the one hand, Zhu Gang, the former general manager of Celgene China, was hired as the chief commercial operation officer (CCO), and a commercialization team was formed for it.
    At the same time, it also signed strategic cooperation with leading domestic dealers and distributors

    .

    02 R&D: Baekje continues to lead, and Clover's R&D expenses have increased by 7 times

    02 R&D: Baekje continues to lead, and Clover's R&D expenses have increased by 7 times

    The research and development of 18A Biotechnology Company is regarded as one of the epitome of the development of the domestic innovative drug industry
    .

    In the past year, 34 biotechnology companies have invested more than 30 billion yuan in research and development, reaching 33.
    425 billion yuan, and the average growth rate of research and development expenses has reached 41%

    .

    R&D investment is an important indicator to measure the R&D level of innovative pharmaceutical companies.
    The increase in R&D investment also represents a pharmaceutical company's entry into an accelerated period of innovation to a certain extent

    .

    Overall, among the 34 biotechnology companies, BeiGene leads the way with R&D investment of 9.
    308 billion yuan

    .

    There is no doubt that BeiGene is still the best
    .
    In 2021, Baiji's R&D investment will reach 9.
    308 billion yuan, a year-on-year increase of 4%

    .
    Although the increase in R&D investment has slowed down, as of the press date, BeiGene is still firmly in the top spot in domestic innovative drug R&D investment

    .
    From the perspective of R&D expenditure in 2020, only BeiGene has invested more than 5 billion yuan in domestic R&D

    .

    The annual report shows that BeiGene has nearly 50 clinical-stage candidates and commercial-stage products, and its R&D pipeline covers various types such as small molecule drugs, monoclonal antibodies, double-antibodies, and ADCs
    .
    Behind the continuous deployment of new targets and new technologies, strong R&D support is required

    .
    At present, Baiji has a huge R&D team of more than 2,900 people as the "engine" of the company's R&D

    .
    Among them, the global clinical development team has reached 2,200 people, and the scale of the development team in the field of oncology is even comparable to that of large multinational pharmaceutical companies

    .

    In terms of global clinical development programs, as of the end of 2021, BeiGene has more than 100 planned or ongoing clinical trials in more than 45 countries and regions, including 38 Phase III or potential registration-available clinical trials
    .
    Global R&D also promotes BeiGene to integrate with international standards more quickly

    .
    According to the annual report, the company expects to update the results data of Baiyueze in a global head-to-head pivotal trial this year, achieve the approval of Baiyueze for CLL indications overseas, and plans to add approvals in more than 10 other countries.

    .
    In addition, the target decision time of the PD-1 drug Bai Zean's first listing application in the FDA is July 12, and it is expected to achieve the first overseas market this year

    .
    According to statistics, since 2015, Baiji's R&D investment has reached about 31.
    6 billion yuan

    .

    Although Baekje is the only company that has invested more than 5 billion yuan in R&D, among the 18A companies this year, the number of club members with R&D exceeding 1 billion yuan has increased from 4 in 2020 to 7
    .
    In addition to BeiGene, six pharmaceutical companies including Zai Lab, Innovent Bio, Junshi Bio, Clover Bio, Kangfang Bio, and Henlius have invested more than 1 billion yuan in research and development in the past year

    .

    The R&D investment has increased by 152%, and Zai Lab has become the "Gold Burning King" second only to Baekje among the 18A companies with an R&D investment of 3.
    655 billion yuan

    .
    Clover Bio, Kangfang Bio, and Fuhong Henlius entered the "R&D over 1 billion club" with R&D investment of 1.
    826 billion yuan, 1.
    123 billion yuan and 1.
    024 billion yuan respectively

    .

    It is worth noting that Clover Bio, which just landed on the Hong Kong stock market on November 5 last year, will increase its R&D investment by 701% in 2021, which is the highest increase among all 18A biotechnology companies that have disclosed their annual reports
    .
    The previous prospectus showed that Clover Bio is a global biotechnology company in the clinical trial stage.
    It was established in 2007 and has not yet achieved profitability

    .

    In September last year, Clover Bio's recombinant protein COVID-19 vaccine candidate SCB-2019 (CpG 1018/aluminum adjuvant) obtained positive results of Phase II/III clinical trials on efficacy and safety, becoming the first batch of randomized double-blind clinical trials One of the new crown vaccines that has demonstrated significant protective efficacy against the Delta strain
    .
    From a technical point of view, the biggest attraction of Clover Bio is its innovative Trimer-Tag™ (protein trimerization) technology platform

    .
    The technology, invented by company founder Dr.
    Liang Peng, can be used to develop dozens of new vaccines and biotherapeutics

    .
    The SCB-2019 new crown vaccine candidate was developed based on the technology platform of trimerization

    .

    Except for Clover Bio, which has doubled its R&D expenditures, a total of 30 18A biotechs will increase their R&D expenditures in 2021
    .
    Among them, Beihai Kangcheng, Yongtai Bio, Connoya, Sinopharm, Zhaoke Ophthalmology, Zai Lab, Kintor, and CanSino Bio have all achieved an increase of over 100% in R&D expenditure

    .

    Of course, it's not all biotech that sees growth in R&D spending
    .
    The R&D investment of four other biotechs has been reduced to varying degrees, including TOT BIOPHARM, Jiahe Biotechnology, Hua Medicine and Tengsheng Boyao

    .
    Among them, the largest decline is Tengsheng Boyao, whose R&D investment in 2021 will drop by 44% year-on-year compared with 2020

    .

    Regarding the reason for the significant reduction in R&D expenditure, Tengsheng Biopharma stated that due to the reduction of third-party contracting costs related to the new crown R&D project, the company's R&D expenditure was reduced by 44%
    .
    Tengsheng Biopharmaceuticals, which entered the Hong Kong stock market in July 2021, has established more than 10 innovative product pipelines, and the fastest R&D progress is in the treatment of new coronary pneumonia and hepatitis

    B.
    Among them, the new crown special drug has been approved for use by the State Food and Drug Administration in December 2021, and an emergency use authorization application has been submitted to the FDA

    .

    Judging from the pipeline disclosed by Tengsheng Biopharmaceuticals, hepatitis B, new coronary pneumonia, HIV (AIDS virus) infection, multidrug-resistant/extensively drug-resistant Gram-negative bacterial infection, multidrug-resistant/extensively drug-resistant Mycobacterium tuberculosis The research and development of new drugs in many fields of infection and depression is the key area of ​​focus.
    Among them, the hepatitis B project is an important research and development pipeline of Tengsheng Biopharmaceuticals, and it has entered clinical phase II

    .
    In addition, projects for HIV treatment and depression treatment are still in Phase I clinical phase, among which depression-related diseases are in the preclinical phase, and the Phase I study of the BRII-296 project for postpartum depression is expected to be completed in the second half of 2022

    .

    03 BD: External acceleration goes to sea, internal modes are diverse

    03 BD: External acceleration goes to sea, internal modes are diverse

    At a time when international innovation has become a major trend, 18A Biotech's overseas license-out project has performed well in the past year
    .

    License-out projects of some Hong Kong stock 18A biotechnology companies in 2021 Image source: Guosheng Securities Research Institute

    Guosheng Securities believes that when local innovation has become the new focus of domestic pharmaceutical companies, the products of innovative pharmaceutical companies from China are narrowing the gap in development speed with international first-in-class products
    .
    Behind the license-out is the establishment of China's innovative drug ecosystem.
    Chinese local innovative companies are also accelerating the establishment and differentiated development of innovative technology platforms, improving the efficiency of new drug development, and entering a larger international market

    .

    According to incomplete statistics, in the past year, BeiGene, Innovent Bio, Junshi Bio, Rongchang Bio, Kintor Pharmaceutical, Keji Pharmaceutical, etc.
    have all achieved overseas licensing cooperation for innovative products

    .
    Among them, BeiGene has twice reached project authorization cooperation with Novartis at the beginning and end of 2021, involving PD-1 and TIGIT products, with a total amount of more than 5 billion US dollars

    .
    And Rongchang Bio's ADC product Vidicitumumab has achieved a single overseas transaction with a total value of 2.
    6 billion US dollars

    .

    On the other hand, while accelerating the export of innovative products to the sea, the cooperation between local pharmaceutical companies has shown the status quo of increasing numbers and diverse models
    .

    Cooperation projects between some Hong Kong-listed 18A biotechnology companies and other local pharmaceutical companies in 2021 Image source: Guosheng Securities Research Institute

    In terms of joint product development and commercialization, small Biotechs use the commercialization capabilities of large Biopharma to commercialize their first products, such as the cooperation between Innovent and Ascentage, so that they can get what they need
    .
    If Biopharma wants to grow into BigPharma, from a big perspective, the R&D capability of new drugs can only be regarded as an entry ticket, and commercialization is an urgent need to overcome.
    The rapid expansion of the commercialization team of local companies requires product support, and small Biotech support products are reduced.
    Risks, large companies realize commercialization and complement each other, and there will be more and more such cooperation in the future

    .

    In addition to product cooperation, a further step is equity cooperation
    .
    Large pharmaceutical companies indirectly enjoy the dividends of innovative drugs through equity cooperation, while small pharmaceutical companies supplement other conditions such as funds through equity cooperation

    .
    In addition to direct shareholding, the form of jointly establishing joint ventures is also popular.
    For example, Junshi Bio and Jiachen Xihai have reached a cooperation agreement.
    The two parties will jointly establish a joint venture to jointly develop and commercialize new drug projects based on mRNA technology platforms and globally.
    ; Nuocheng Jianhua and Connoya signed a joint venture agreement to establish a joint venture Tiannuo Jiancheng in a 50:50 ratio to discover, develop and commercialize related innovative drugs on a global scale

    .
    CanSino has established a joint venture with Shanghai Pharmaceutical Group for the production and supply of adenovirus vector new crown vaccine Keweisha

    .

    As local pharmaceutical companies promote the transformation of local R&D achievements through cooperation and investment, in the future, the cooperation methods between local pharmaceutical companies will also be more in-depth and diverse
    .

    Original title: The top BioPharma commercialization test report card: 34 18A pharmaceutical companies have a revenue of 25.
    3 billion yuan!
    60% of the market value shrinks, where will small and beautiful biotech go?

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.